The EndoInjector (Previously known as the Endoshield) is the latest generation device to enable delivery of a corneal graft for Descemet’s Stripping Endothelial Keratoplasty (DSEK). This device is designed for simple one handed use and can deliver an 8 to 9 mm DSEK graft through a clear corneal incision as small as 3.2 mm. Clinical studies have shown that injection of the DSEK graft with the EndoInjector produces only about 13% endothelial cell loss, which is significantly lower than that reported for folding techniques.
According to Dr. Juan Carlos Abad, a Harvard trained corneal surgeon practicing in Medellin, Colombia.
“The EndoInjector has simplified enormously my DSAEK surgery, having been able to do it through a small corneal incision under topical anesthesia! Compared to the other DSAEK surgical techniques, the EndoInjector has become like the time-old comparison of phacoemulsification vs extracapsular cataract extraction. The Endoshield seems to be gentle to the corneal endothelium, the typical patient has a clear cornea with excellent visual acuity since day one and with almost a year of follow-up no undue corneal trauma has been noted so far.” – Juan Carlos Abad, MD (Click here to visit Dr. Abad’s website)
The EndoInjector has European CE Mark approval and is available for sale in the European Union and other countries. The EndoInjector is pending 510k clearance in the U.S.
The EndoInjector has received European CE Mark approval and is used by cornea surgeons around the world. The EndoInjector has not yet received U.S. FDA Clearance and is limited in the United States to investigational use only.